While Aker BioMarine’s Q3 2025 results demonstrate solid growth, particularly in its core Human Health Ingredients segment, the challenges in Consumer Health Products and the stock market’s negative ...

The following slide details the evolution of key balance sheet metrics over time: This strong financial position aligns with the data from the previous quarter, where the company reported a current ...

Diodes Incorporated (NASDAQ:DIOD) presented its third quarter 2025 financial results on November 6, revealing continued revenue growth despite margin pressures from product mix shifts. The ...

Aker BioMarine (OB:AKBM) presented its third quarter 2025 results on October 31, highlighting a 15% year-over-year revenue increase to $56.8 million, while adjusted EBITDA surged 50% to $12.2 million.